0001209191-21-023135.txt : 20210325
0001209191-21-023135.hdr.sgml : 20210325
20210325213639
ACCESSION NUMBER: 0001209191-21-023135
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210325
FILED AS OF DATE: 20210325
DATE AS OF CHANGE: 20210325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Edris Badreddin
CENTRAL INDEX KEY: 0001786966
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 21774382
MAIL ADDRESS:
STREET 1: C/O SPRINGWORKS THERAPEUTICS, INC.
STREET 2: 100 WASHINGTON BLVD.
CITY: STAMFORD
STATE: CT
ZIP: 06902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-739-6451
MAIL ADDRESS:
STREET 1: C/O ORBIMED ADVISORS LLC
STREET 2: 601 LEXINGTON AVE, 54TH FLR.
CITY: NEW YORK
STATE: NY
ZIP: 10022
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-03-25
0
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001786966
Edris Badreddin
C/O EDGEWISE THERAPEUTICS, INC.
3145 COLORADO AVE.
BOULDER
CO
80303
1
0
0
0
Common Stock
19820
D
Stock Option (Right to Buy)
0.39
2028-04-26
Common Stock
13960
D
Stock Option (Right to Buy)
0.64
2029-11-14
Common Stock
17236
D
Stock Option (Right to Buy)
0.71
2030-09-01
Common Stock
7605
D
Stock Option (Right to Buy)
1.93
2030-12-15
Common Stock
10463
D
Stock Option (Right to Buy)
1.93
2031-02-03
Common Stock
66477
D
1/4th of the shares subject to the option became vested and exercisable on March 4, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
1/48th of the shares subject to the option became vested and exercisable on November 16, 2019 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
1/48th of the shares subject to the option became vested and exercisable on October 2, 2020 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
1/48th of the shares subject to the option became vested and exercisable on January 3, 2021 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
The shares of Common Stock underlying the option are subject to an early exercise provision and are immediately exercisable. 1/36th of the shares subject to the option will become vested on March 3, 2021 and 1/36th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
Exhibit 24 - Power of Attorney
/s/John R. Moore Attorney-in-Fact for Badreddin Edris
2021-03-25
EX-24.3_975592
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Edgewise Therapeutics, Inc.
(the Company), hereby constitutes and appoints Kevin Koch, Ph.D., R. Michael
Carruthers and John R. Moore, and each of them, as the true and lawful
attorney-in-fact of the undersigned to:
1. prepare, execute in the name of the undersigned and on the behalf of the
undersigned, and submit the Securities and Exchange Commission (the SEC) a Form
ID, including amendments thereto, and any other documents necessary or
appropriate to obtain EDGAR codes and passwords enabling the undersigned to make
electronic filings with the SEC or reports required by Section 16(a) of the
Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. complete and execute Forms 3, 4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the ownership, acquisition
or disposition of securities of the Company by the undersigned; and
2. do all acts necessary in order to file such forms with the SEC, any
securities exchange or national association, the Company and such other person
or agency as the attorneys-in-fact shall deem appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the responsibilities of the undersigned to comply with Section
16 of the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
holdings of the undersigned of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 16th day of March, 2021.
Signature: /s/ Badreddin Edris, Ph.D.
Print Name: Badreddin Edris, Ph.D.